ADHD Issues. Learn about ADHD (Attention deficit hyperactivity disorder) and Childhood hyperkinesis
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Youth Suicide Warnings Are Slowing Antidepressant Sales

Study finds drop in SSRI prescriptions for children and adults

MONDAY, Jan. 7 (HealthDay News) -- Warnings about the risk of suicidal thoughts and behaviors in young people who take antidepressants may be slowing the pace of antidepressant prescriptions, new research suggests.

The U.S. Food and Drug Administration first became aware of the possibility that antidepressants and selective serotonin reuptake inhibitors (SSRIs) might increase the risk of thoughts of suicide and suicidal behavior in children and adults in the early 1990s. By October 2004, the FDA had issued a general warning about the increased risk for youths taking antidepressants.

Advertisement
Related Stories
 border=
Neighborhood Alcohol Outlets Tied to Kids' Injury Risk
Research Unveils Earliest Cell Changes in Down Syndrome
Kids of Stressed, Low-Income Moms Prone to Weight Problems
Related Videos
 border=
Video Games for ADHD
ADHD Patch
Diet Makes An Impact On Adhd
Related Slides
 border=
ADHD
Fetal Development
Related Encyclopedia
 border=
Attention Deficit/Hyperactivity Disorder


Researchers at Columbia University Medical Center, New York, evaluated trends in prescriptions for antidepressants using data from Medco, a company that manages prescription drug benefits. They looked at antidepressant prescriptions by age: youth age 6 to 17; adults age 18 to 64; and seniors over age 65. They then compared prescription data by age group for three time periods: before the warnings were issued (May 1, 2002 to June 19, 2003); the warning specific to medications such as Paxil, which contains the SSRI paroxetine (June 20, 2003, to Oct. 15, 2004); and the universal or black box warning (Oct. 16, 2004, to Dec. 31, 2005).

The researchers found that the paroxetine warning resulted in lower prescriptions of paroxetine for young people and, to a lesser degree, older adults, as well. Other antidepressants continued to be prescribed at their previous levels.

However, after the more general black box warning, the researchers saw a "statistically nonsignificant" reduction in the use of all antidepressants to treat youths, but a significant drop in the use of all SSRIs in addition to paroxetine.

The researchers noted that between 1985 and 1990, antidepressant prescriptions quadrupled. The recent warnings have moderately slowed the use of antidepressant prescriptions, particularly for young people, concluded the researchers.

The study was published in the January issue of Archives of General Psychiatry.

More information

To learn more about the treatment options available to people with mental illness, visit the National Institutes of Health.

-- Madeline Vann

SOURCE: JAMA/Archives journals, news release, Jan. 7, 2008

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 1/7/2008



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Sep 5, 2008
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: